Zika Virus: Medical Countermeasure Development Challenges

Zika Response Working Group

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

Introduction: Reports of high rates of primary microcephaly and Guillain–Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infectious public health threat. There are no licensed medical countermeasures (vaccines, therapies or preventive drugs) available for Zika virus infection and disease. The Pan American Health Organization (PAHO) predicts that Zika virus will continue to spread and eventually reach all countries and territories in the Americas with endemic Aedes mosquitoes. This paper reviews the status of the Zika virus outbreak, including medical countermeasure options, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for medical countermeasure development and deployment. Methods: Multiple information sources were employed to support the review. These included publically available literature, patents, official communications, English and Lusophone lay press. Online surveys were distributed to physicians in the US, Mexico and Argentina and responses analyzed. Computational epitope analysis as well as infectious disease outbreak modeling and forecasting were implemented. Field observations in Brazil were compiled and interviews conducted with public health officials.

Original languageEnglish (US)
Article numbere0004530
JournalPLoS Neglected Tropical Diseases
Volume10
Issue number3
DOIs
StatePublished - Mar 2 2016
Externally publishedYes

Fingerprint

Disease Outbreaks
Brazil
Public Health
Pan American Health Organization
Polynesia
Insect Vectors
Active Immunotherapy
Microcephaly
Virology
Patents
Aedes
Argentina
Mexico
Allergy and Immunology
Culicidae
Epitopes
Epidemiology
Communication
Interviews
Viruses

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zika Virus : Medical Countermeasure Development Challenges. / Zika Response Working Group.

In: PLoS Neglected Tropical Diseases, Vol. 10, No. 3, e0004530, 02.03.2016.

Research output: Contribution to journalReview article

Zika Response Working Group. / Zika Virus : Medical Countermeasure Development Challenges. In: PLoS Neglected Tropical Diseases. 2016 ; Vol. 10, No. 3.
@article{c8782115686041daa96ff9898160ce7a,
title = "Zika Virus: Medical Countermeasure Development Challenges",
abstract = "Introduction: Reports of high rates of primary microcephaly and Guillain–Barr{\'e} syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infectious public health threat. There are no licensed medical countermeasures (vaccines, therapies or preventive drugs) available for Zika virus infection and disease. The Pan American Health Organization (PAHO) predicts that Zika virus will continue to spread and eventually reach all countries and territories in the Americas with endemic Aedes mosquitoes. This paper reviews the status of the Zika virus outbreak, including medical countermeasure options, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for medical countermeasure development and deployment. Methods: Multiple information sources were employed to support the review. These included publically available literature, patents, official communications, English and Lusophone lay press. Online surveys were distributed to physicians in the US, Mexico and Argentina and responses analyzed. Computational epitope analysis as well as infectious disease outbreak modeling and forecasting were implemented. Field observations in Brazil were compiled and interviews conducted with public health officials.",
author = "{Zika Response Working Group} and Malone, {Robert W.} and Jane Homan and Callahan, {Michael V.} and Jill Glasspool-Malone and Lambodhar Damodaran and Schneider, {Adriano De Bernardi} and Rebecca Zimler and James Talton and Cobb, {Ronald R.} and Ivan Ruzic and Julie Smith-Gagen and Daniel Janies and James Wilson and David Hone and Stefanie Hone and Sina Bavari and Veronica Soloveva and Scott Weaver",
year = "2016",
month = "3",
day = "2",
doi = "10.1371/journal.pntd.0004530",
language = "English (US)",
volume = "10",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Zika Virus

T2 - Medical Countermeasure Development Challenges

AU - Zika Response Working Group

AU - Malone, Robert W.

AU - Homan, Jane

AU - Callahan, Michael V.

AU - Glasspool-Malone, Jill

AU - Damodaran, Lambodhar

AU - Schneider, Adriano De Bernardi

AU - Zimler, Rebecca

AU - Talton, James

AU - Cobb, Ronald R.

AU - Ruzic, Ivan

AU - Smith-Gagen, Julie

AU - Janies, Daniel

AU - Wilson, James

AU - Hone, David

AU - Hone, Stefanie

AU - Bavari, Sina

AU - Soloveva, Veronica

AU - Weaver, Scott

PY - 2016/3/2

Y1 - 2016/3/2

N2 - Introduction: Reports of high rates of primary microcephaly and Guillain–Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infectious public health threat. There are no licensed medical countermeasures (vaccines, therapies or preventive drugs) available for Zika virus infection and disease. The Pan American Health Organization (PAHO) predicts that Zika virus will continue to spread and eventually reach all countries and territories in the Americas with endemic Aedes mosquitoes. This paper reviews the status of the Zika virus outbreak, including medical countermeasure options, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for medical countermeasure development and deployment. Methods: Multiple information sources were employed to support the review. These included publically available literature, patents, official communications, English and Lusophone lay press. Online surveys were distributed to physicians in the US, Mexico and Argentina and responses analyzed. Computational epitope analysis as well as infectious disease outbreak modeling and forecasting were implemented. Field observations in Brazil were compiled and interviews conducted with public health officials.

AB - Introduction: Reports of high rates of primary microcephaly and Guillain–Barré syndrome associated with Zika virus infection in French Polynesia and Brazil have raised concerns that the virus circulating in these regions is a rapidly developing neuropathic, teratogenic, emerging infectious public health threat. There are no licensed medical countermeasures (vaccines, therapies or preventive drugs) available for Zika virus infection and disease. The Pan American Health Organization (PAHO) predicts that Zika virus will continue to spread and eventually reach all countries and territories in the Americas with endemic Aedes mosquitoes. This paper reviews the status of the Zika virus outbreak, including medical countermeasure options, with a focus on how the epidemiology, insect vectors, neuropathology, virology and immunology inform options and strategies available for medical countermeasure development and deployment. Methods: Multiple information sources were employed to support the review. These included publically available literature, patents, official communications, English and Lusophone lay press. Online surveys were distributed to physicians in the US, Mexico and Argentina and responses analyzed. Computational epitope analysis as well as infectious disease outbreak modeling and forecasting were implemented. Field observations in Brazil were compiled and interviews conducted with public health officials.

UR - http://www.scopus.com/inward/record.url?scp=84962418537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962418537&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0004530

DO - 10.1371/journal.pntd.0004530

M3 - Review article

C2 - 26934531

AN - SCOPUS:84962418537

VL - 10

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 3

M1 - e0004530

ER -